Purohit Sharad, Podolsky Robert, Collins Christin, Zheng Weipeng, Schatz Desmond, Muir Andy, Hopkins Diane, Huang Yi-Hua, She Jin-Xiong
Center for Biotechnology and Genomic Medicine, Medical College of Georgia, CA4095 Augusta, GA 30912.
Department of Pediatrics, University of Florida, Gainesville FL 32607, USA.
J Autoimmune Dis. 2005 Oct 31;2:8. doi: 10.1186/1740-2557-2-8.
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) plays a critical role in downregulation of antigen-activated immune response and polymorphisms at the CTLA-4 gene have been shown to be associated with several autoimmune diseases including type-1 diabetes (T1D). The etiological mutation was mapped to the CT60-A/G single nucleotide polymorphism (SNP) that is believed to control the processing and production of soluble CTLA-4 (sCTLA-4).
We therefore determined sCTLA-4 protein levels in the sera from 82 T1D patients and 19 autoantibody positive (AbP) subjects and 117 autoantibody negative (AbN) controls using ELISA. The CT-60 SNP was genotyped for these samples by using PCR and restriction enzyme digestion of a 268 bp DNA segment containing the SNP. Genotyping of CT-60 SNP was confirmed by dye terminating sequencing reaction.
Higher levels of sCTLA-4 were observed in T1D (2.24 ng/ml) and AbP (mean = 2.17 ng/ml) subjects compared to AbN controls (mean = 1.69 ng/ml) with the differences between these subjects becoming significant with age (p = 0.02). However, we found no correlation between sCTLA-4 levels and the CTLA-4 CT-60 SNP genotypes.
Consistent with the higher serum sCTLA-4 levels observed in other autoimmune diseases, our results suggest that sCTLA-4 may be a risk factor for T1D. However, our results do not support the conclusion that the CT-60 SNP controls the expression of sCTLA-4.
细胞毒性T淋巴细胞相关抗原4(CTLA-4)在下调抗原激活的免疫反应中起关键作用,并且CTLA-4基因的多态性已被证明与包括1型糖尿病(T1D)在内的多种自身免疫性疾病相关。病因突变被定位到CT60-A/G单核苷酸多态性(SNP),该多态性被认为控制可溶性CTLA-4(sCTLA-4)的加工和产生。
因此,我们使用酶联免疫吸附测定法(ELISA)测定了82例T1D患者、19例自身抗体阳性(AbP)受试者和117例自身抗体阴性(AbN)对照者血清中的sCTLA-4蛋白水平。通过对包含该SNP的268 bp DNA片段进行聚合酶链反应(PCR)和限制性酶切来对这些样本进行CT-60 SNP基因分型。通过染料终止测序反应确认CT-60 SNP的基因分型。
与AbN对照者(平均 = 1.69 ng/ml)相比,T1D患者(2.24 ng/ml)和AbP受试者(平均 = 2.17 ng/ml)中观察到更高水平的sCTLA-4,这些受试者之间的差异随年龄增长变得显著(p = 0.02)。然而,我们发现sCTLA-4水平与CTLA-4 CT-60 SNP基因型之间没有相关性。
与在其他自身免疫性疾病中观察到的较高血清sCTLA-4水平一致,我们的结果表明sCTLA-4可能是T1D的一个风险因素。然而,我们的结果不支持CT-60 SNP控制sCTLA-4表达的结论。